Placebo effects on all-cause mortality of patients with COVID-19 in randomized controlled trials of interleukin 6 antagonists: A systematic review and network meta-analysis
Journal
Psychiatry and clinical neurosciences
Date Issued
2023-08-30
Author(s)
Tseng, Ping-Tao
Zeng, Bing-Syuan
Thompson, Trevor
Stubbs, Brendon
Su, Kuan-Pin
Chen, Yen-Wen
Chen, Tien-Yu
Wu, Yi-Cheng
Lin, Pao-Yen
Carvalho, Andre F
Hsu, Chih-Wei
Li, Dian-Jeng
Yeh, Ta-Chuan
Sun, Cheuk-Kwan
Cheng, Yu-Shian
Shiue, Yow-Ling
Liang, Chih-Sung
Abstract
Many randomized controlled trials (RCTs) have investigated the use of interleukin 6 antagonists for the treatment of coronavirus disease 2019 (COVID-19), yielding inconsistent results. This network meta-analysis (NMA) aimed to identify the source of these inconsistent results by reassessing whether participants treated with standard of care (SoC) plus placebo have different all-cause mortality from those treated with SoC alone and to reevaluate the efficacy of interleukin 6 antagonists in the treatment of COVID-19.
Subjects
COVID-19; coronavirus disease 2019; interleukin 6; network meta-analysis; placebo effect
SDGs
Type
journal article